Medicare Is Covering GLP-1s Starting July 1 — Here's Exactly How to Qualify

What Is the Medicare GLP-1 Bridge?

The Medicare GLP-1 Bridge is a short-term demonstration run by the Centers for Medicare & Medicaid Services (CMS) that provides eligible Medicare Part D beneficiaries with access to certain GLP-1 receptor agonist medications. The program runs from July 1, 2026, through December 31, 2027.

This is a massive shift. For years, Medicare explicitly excluded coverage of anti-obesity medications, leaving millions of older Americans — the fastest-growing GLP-1 demographic — paying entirely out of pocket or going without treatment. The Bridge changes that, at least temporarily, while CMS collects utilization data ahead of a more permanent program called BALANCE.

Who Qualifies for the Medicare GLP-1 Bridge?

The eligibility criteria center on Medicare Part D enrollment and clinical indications. You must be enrolled in a Medicare Part D plan, have a qualifying diagnosis (obesity with BMI ≥30, or overweight with BMI ≥27 plus at least one weight-related comorbidity), and receive a prior authorization from a licensed prescriber.

Important details your doctor should know: CMS is using a single central processor to manage prior authorization, claims adjudication, and payment for the Bridge program. This means the process is standardized — it does not vary by plan sponsor. The prior authorization form is available on the CMS website, but requests were not accepted before July 1, 2026.

What Does the Bridge Cover?

The program covers FDA-approved GLP-1 receptor agonists indicated for chronic weight management. This includes brand-name injectable semaglutide (Wegovy), oral semaglutide (Wegovy pill), tirzepatide (Zepbound), and the newly approved higher-dose semaglutide 7.2mg (Wegovy HD). Compounded GLP-1 medications are not covered under this demonstration.

The cost-sharing structure follows standard Part D rules with some modifications specific to the Bridge. Expect reduced copays compared to retail pricing, though the exact out-of-pocket cost will depend on your specific plan and the medication selected.

What Comes After the Bridge?

CMS designed the Bridge as a data-gathering exercise. The information collected — utilization rates, adherence patterns, health outcomes, and cost data — will feed directly into the BALANCE Model, which launched in Medicaid as early as May 2026 and is set to expand into Medicare Part D in January 2027.

The BALANCE Model is a voluntary program for manufacturers, states, and plans that aims to make GLP-1 medications permanently accessible while controlling costs. If the Bridge data supports the cost-effectiveness argument (which cardiovascular outcome trials strongly suggest it will), this could pave the way for permanent Medicare coverage of anti-obesity medications.

What This Means for Your Treatment Plan

If you are a Medicare beneficiary who has been paying out of pocket for GLP-1 medications — or who has wanted to start but could not afford it — this is your window. Here is what to discuss with your prescriber:

• Timing matters. The program starts accepting prior authorizations on July 1. If you already have a relationship with a prescriber, schedule an appointment now to get paperwork ready.
• Brand-name only. The Bridge covers FDA-approved medications, not compounded alternatives. If you are currently on a compounded GLP-1, discuss transitioning to a brand-name option with your doctor.
• Continuity of care. If you have been on a GLP-1 through a telehealth provider, your prescriber can submit the prior authorization through the CMS central processor. You do not need to switch to an in-person physician.
• Document everything. The prior authorization requires clinical documentation. Ask your doctor to include all weight-related diagnoses in your chart — not just BMI.

For patients who are not yet on a GLP-1 but may qualify, the Medicare GLP-1 Bridge removes the single biggest barrier that has kept older adults from accessing these medications: cost.